We are live on ! Find out more
KNSA icon

Kiniksa Pharmaceuticals
KNSA

102 hedge funds and large institutions have $402M invested in Kiniksa Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 37 increasing their positions, 31 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 31

1.7% less ownership

Funds ownership: 90.98% → 89.28% (-1.7%)

2% less funds holding

Funds holding: 104 → 102 (-2)

12% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 17

25% less capital invested

Capital invested by funds: $537M → $402M (-$135M)

34% less call options, than puts

Call options by funds: $2.87M | Put options by funds: $4.33M

Holders
102
Holders Change
-2
Holders Change %
-1.92%
% of All Funds
1.78%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
37
Reduced
31
Closed
17
Calls
$2.87M
Puts
$4.33M
Net Calls
-$1.46M
Net Calls Change
-$336K

Top Buyers

1
State Street
State Street
Massachusetts
+$13.4M
2
PAMU
Pictet Asset Management (UK)
United Kingdom
+$12.9M
3
OM
Opaleye Management
Massachusetts
+$12.7M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$6.08M
5
LGM
Logos Global Management
California
+$6.08M

Top Sellers

1
Ameriprise
Ameriprise
Minnesota
-$25.4M
2
APM
Avidity Partners Management
Texas
-$24.6M
3
Citadel Advisors
Citadel Advisors
Florida
-$13.7M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$4.07M
5
Barclays
Barclays
United Kingdom
-$3.58M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
26
Citigroup
New York
$2.21M +$333K +21,894 +16%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$1.83M -$46.4K -3,056 -2%
Citadel Advisors
28
Citadel Advisors
Florida
$1.69M -$13.7M -900,239 -88%
N
29
Nuveen
North Carolina
$1.44M +$175K +11,543 +13%
Rafferty Asset Management
30
Rafferty Asset Management
New York
$1.44M +$587K +38,673 +60%
Susquehanna International Group
31
Susquehanna International Group
Pennsylvania
$1.32M +$519K +34,140 +56%
Deutsche Bank
32
Deutsche Bank
Germany
$1.11M -$547K -35,980 -31%
Two Sigma Advisers
33
Two Sigma Advisers
New York
$1.01M -$661K -43,500 -38%
Charles Schwab
34
Charles Schwab
California
$980K +$73.7K +4,850 +7%
PPA
35
Parametric Portfolio Associates
Washington
$914K -$99.6K -6,555 -9%
RJA
36
Raymond James & Associates
Florida
$825K +$326K +21,458 +57%
Ensign Peak Advisors
37
Ensign Peak Advisors
Utah
$740K – – –
Swiss National Bank
38
Swiss National Bank
Switzerland
$736K -$21.3K -1,400 -3%
Two Sigma Investments
39
Two Sigma Investments
New York
$686K +$748K +49,232 New
Jacobs Levy Equity Management
40
Jacobs Levy Equity Management
New Jersey
$657K -$50.7K -3,335 -7%
Los Angeles Capital Management
41
Los Angeles Capital Management
California
$638K +$356K +23,463 +105%
CAN
42
Cetera Advisor Networks
California
$608K +$26.1K +1,720 +4%
HWAM
43
Hennion & Walsh Asset Management
New Jersey
$601K +$655K +43,116 New
AA
44
ALPS Advisors
Colorado
$593K -$223K -14,659 -26%
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$560K -$1.19K -78 -0.2%
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$508K +$117K +7,675 +27%
Bank of America
47
Bank of America
North Carolina
$474K -$378K -24,852 -42%
VEA
48
Virtus ETF Advisers
New York
$456K +$264K +17,348 +113%
Wells Fargo
49
Wells Fargo
California
$455K -$1.32M -87,057 -73%
AllianceBernstein
50
AllianceBernstein
Tennessee
$454K +$161K +10,600 +48%
1
2
3 4 5

KNSA Hedge Fund Activity: Q2 2021 in Review

102 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q2 2021, worth a combined $402M — down 25% from $537M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of KNSA and 15 opened new positions — a net loss of 2 holders — while 31 trimmed existing stakes and 37 added.

The largest buyer was State Street, adding an estimated $13.4M. The largest seller was Ameriprise, exiting entirely with an estimated $25.4M sold.

  • 102 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q2 2021, down from 104 in Q1 2021.
  • Funds reported $402M of Kiniksa Pharmaceuticals stock for Q2 2021, down 25% quarter-over-quarter.
  • 15 funds opened new Kiniksa Pharmaceuticals positions in Q2 2021 and 17 closed out, a net change of -2 holders.
  • The largest Kiniksa Pharmaceuticals buyer in Q2 2021 was State Street, an estimated $13.4M added.
  • The largest Kiniksa Pharmaceuticals seller in Q2 2021 was Ameriprise, an estimated $25.4M sold.

Based on aggregated 13F filings for Q2 2021.